A 12-month, Prospective, Randomized, Active-controlled, Open-label Study to Evaluate the Patient Retention of Fingolimod vs. Approved First-line Disease Modifying Therapies in Adults With Relapsing Remitting Multiple Sclerosis

Trial Profile

A 12-month, Prospective, Randomized, Active-controlled, Open-label Study to Evaluate the Patient Retention of Fingolimod vs. Approved First-line Disease Modifying Therapies in Adults With Relapsing Remitting Multiple Sclerosis

Completed
Phase of Trial: Phase IV

Latest Information Update: 28 Apr 2017

At a glance

  • Drugs Fingolimod (Primary) ; Glatiramer acetate; Interferon beta-1a; Interferon beta-1b
  • Indications Multiple sclerosis
  • Focus Therapeutic Use
  • Acronyms PREFERMS
  • Sponsors Novartis Pharmaceuticals
  • Most Recent Events

    • 28 Apr 2017 Results (n=776) presented at the 69th Annual Meeting of the American Academy of Neurology.
    • 28 Apr 2017 Results comparing rate of infection with absolute lymphocyte counts presented at the 69th Annual Meeting of the American Academy of Neurology
    • 28 Apr 2017 Primary endpoint has been met. (Retention on treatment) as per result presented at the 69th Annual Meeting of the American Academy of Neurology
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top